Skip to main content
Home > SciBX > Translational Notes

Chronological Index of : Translational Notes

 Current Issue
  • Animal instincts

    A workshop convened by the NINDS has proposed a set of standards for designing and reporting on animal studies. The challenges will be to implement the standards throughout the research community and determine which …

    Published on 11/8/2012
  • Table 1: CPRIT's commercial portfolio

    Translational Notes: Mess with Texas Table 1. CPRIT's commercial portfolio. The Cancer Prevention & Research Institute of Texas (CPRIT) has issued about $760 million in funding to academic researchers, community …

    Published on 11/1/2012
  • From bedside to bench

    The recently announced oncology R&D collaboration between Sanofi and Massachusetts General Hospital takes a different tack than most translational research partnerships by starting with insights gleaned from the bedside…

    Published on 11/1/2012
  • Mess with Texas

    The disintegration of the Cancer Prevention & Research Institute of Texas' scientific board is a lesson in how not to manage perceived conflict between commercial and scientific interests at philanthropic research …

    Published on 11/1/2012
  • China's new mAb institute

    The launch of the Shanghai Institute for Advanced Immunochemical Studies marks China's first attempt to establish a center of antibody research on par with research centers in the U.S. and Europe. SIIS will identify …

    Published on 10/25/2012
  • Table 1: Programs on TAP

    Translational Notes: Leukemia team building Table 1. Programs on TAP. The Leukemia & Lymphoma Society (LLS) has partnered with academic institutions or biotech companies to fund the development of at least 14 …

    Published on 10/11/2012
  • Leukemia team building

    The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene to solicit and fund proposals from academics and smaller …

    Published on 10/11/2012
  • Buddy system for orphan disease

    The Wellcome Trust has launched a program to fund early stage translational research in rare and orphan diseases. The Pathfinder Award Scheme requires academics to pair up with an industry partner at the outset.

    Published on 10/4/2012
  • The cost of reproducibility

    The newly launched Reproducibility Initiative could help researchers validate the key findings of their preclinical research programs and improve the chances of attracting investors and partners. However, precise …

    Published on 8/30/2012
  • AZ goes APOE

    AstraZeneca has assembled an academia-industry consortium to unravel the role of apolipoprotein E in Alzheimer's disease. The team hopes to uncover basic mechanisms about how APOE drives the disease process and to …

    Published on 8/2/2012
  • Biogen interacts with target discovery

    Biogen Idec is taking advantage of advances in the study of protein-protein interactions to generate the first comprehensive human interactome. In collaboration with Harvard Medical School researchers, the company will …

    Published on 7/26/2012
  • Immunotherapy alliance for T1D

    JDRF and Novo Nordisk have forged an R&D collaboration that leverages the foundation's research networks and databases and the pharma's R&D capabilities to discover and develop new immunotherapies for type 1 diabetes.

    Published on 7/12/2012
  • Table 1: Repurposing pharma compounds

    Pharma compounds at the crossroads Table 1. Repurposing pharma compounds. Source: BCIQ: BioCentury Online Intelligence; National Center for Advancing Translational Sciences (NCATS) website Company Compound …

    Published on 6/28/2012
  • Pharma compounds at the crossroads

    NIH's National Center for Advancing Translational Sciences has disclosed details about the first library of therapeutics in its New Therapeutic Uses for Existing Molecules program. Although it is not yet clear how …

    Published on 6/28/2012
  • GSK completes its Canadian tripod

    GlaxoSmithKline has announced its third major academic collaboration in Canada in the past two years -- a deal with the Centre for Drug Research and Development to identify and fund academic research in the country.

    Published on 6/21/2012
  • Table 1: Trajectories of recipients of the California Institute for Quantitative Biosciences' (QB3) Bridging-the-Gap Awards

    Translational Notes: Building bridges Table 1. Trajectories of recipients of the California Institute for Quantitative Biosciences' (QB3) Bridging-the-Gap Awards. Principal investigator QB3 campus Award year …

    Published on 5/3/2012
  • Building bridges

    Johnson & Johnson has joined the ranks of funders supporting the California Institute for Quantitative Biosciences Bridging-the-Gap Awards by providing two grants for research on an implantable pancreas for type 1 …

    Published on 5/3/2012
  • Table 1: Cancer Prevention & Research Institute of Texas' latest grant recipients

    Texas translation Table 1. Cancer Prevention & Research Institute of Texas' latest grant recipients. Recipient Program Funding ($M) Companies Asuragen Inc. Mutational profiling of tumors by next-generation DNA …

    Published on 4/26/2012
  • Texas translation

    The taxpayer-backed Cancer Prevention & Research Institute of Texas is moving downstream from its initial focus on basic research in oncology. This month, the institute announced its latest round of grants--this time …

    Published on 4/26/2012
  • Table 1

    Building tools against autism Table 1. Participants in the European Autism Interventions-A Multicentre Study for Developing New Medications (EU-AIMS) consortium. Academic centers and research organizations …

    Published on 4/19/2012
  • Building tools against autism

    An academic-industry consortium headed by King's College London and Roche launched this month with €29.6 million ($38.9 million) to develop research tools and diagnostics for autism spectrum disorder and to help select …

    Published on 4/19/2012
  • Phenotypic screening, take two

    Phenotypic screening for drug discovery is making a comeback, but not everybody is embracing it. Some pharmas, such as Novartis and GSK, are placing a bet on phenotypic screening, whereas others, such as Genentech, are …

    Published on 4/12/2012
  • Merck's reCalibration

    Merck is investing up to $90 million over the next seven years to fund the California Institute for Biomedical Research. The pharma is hoping the wide spectrum of translational research to be covered by the institute …

    Published on 3/22/2012
  • One gap, two approaches

    Whereas most academic institutes tackle the translational gap by pushing their assets further along in hopes of attracting an industry partner, University Hospitals is taking the opposite approach by forming a company …

    Published on 3/15/2012
  • Personalized medicine triumvirate

    Three Florida-based institutions are pooling resources in the Personalized Medicine Partnership of Florida to accelerate the discovery of markers that could predict individual responses to cancer, metabolic and …

    Published on 3/1/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993